CompletedNot Applicable

Quantitative Parameters of HLA-DQ Antibodies in Lung Transplantation

France88 participantsStarted 2018-03-14

Plain-language summary

The aim is to compare the quantitative parameters of de novo anti-HLA DQ Donor Specific Antibodies (DSA), determined at the time of their discovery by surface plasmon resonance (SPR), between recipients that developed a Chronic Lung Allograft Dysfunction (CLAD) for the 2 years following DSA apparition and those who did not. If concentration, kinetics and/or affinity parameters of anti-DQ DSA are associated with CLAD development, new, non-invasive prognostic biomarkers of humoral rejection in lung transplantation will be discovered .

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 years and older * Patient transplanted between 01/01/2001 and 31/07/2016 * Patient with immunodominant anti-HLA DQ de novo DSA developed before 08/2016 * Patient for who sufficient remaining serum quantity is available in usual care biobank * non-opposition of the patient Exclusion Criteria: * preformed DSA at the transplantation; * Non immunodominant DQ DSA ; * Insufficient serum quantity in usual care biobank * Inability to determine the date of DSA apparition at around one year * opposition of the patient

What they're measuring

CLAD development

Timeframe: 2 years

Trial details

NCT IDNCT03474536

SponsorUniversity Hospital, Bordeaux

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-04-08

View on ClinicalTrials.gov More Lung Transplantation trials